Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

YURDANUR ERDOĞAN; NİLGÜN YILMAZ DEMİRCİ; Sertaç BÜYÜKYAYLACI ÖZDEN; Tuğçe Şahin ÖZDEMİREL; Berna AKINCI ÖZYÜREK

Journals / Solunum / 2016 / Cilt: 18 - Sayı: 1

Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

YURDANUR ERDOĞAN

NİLGÜN YILMAZ DEMİRCİ

Sertaç BÜYÜKYAYLACI ÖZDEN

Tuğçe Şahin ÖZDEMİREL

Berna AKINCI ÖZYÜREK

Journal: Solunum
Issue: 2016 · Cilt: 18 - Sayı: 1
Pages: 61–62
DOI: —

🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.

DergiPark Record ↗

🔖

Cite This Article

ERDOĞAN, Y., DEMİRCİ, N. Y., ÖZDEN, S. B., ÖZDEMİREL, T. Ş., ÖZYÜREK, B. A. (2016). Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Solunum, Cilt: 18 - Sayı: 1, 61–62. https://ajindex.com/articles/314253

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (2)

Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, et al. Nonsteroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134. Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanip. Drug Des Devel Ther 2015: 9: 6407-19.
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial ofpirfenidone in patients with idiopathic pulmo- nary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-7. [CrossRef] Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenido- ne in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9. [CrossRef] Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-53. CrossRef]